Objective/background: Here, we described the clinical characteristics and outcomes of central nervous system (CNS) infections occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a single institution over the previous 6 years. Methods: Charts of 353 consecutive allogeneic transplant recipients were retrospectively reviewed for CNS infection. Results: A total of 17 cases of CNS infection were identified at a median of 38 days (range, 10-1028 days) after allo-HSCT. Causative pathogens were human herpesvirus-6 (n = 6), enterococcus (n = 2), staphylococcus (n = 2), streptococcus (n = 2), varicella zoster virus (n = 1), cytomegalovirus (n = 1), John Cunningham virus (n = 1), adenovirus (n = 1), and Toxoplasma gondii (n = 1). The cumulative incidence of CNS infection was 4.1% at 1 year and 5.5% at 5 years. Conclusion: Multivariate analysis revealed that high-risk disease status was a risk factor for developing CNS infection (p = .02), and that overall survival at 3 years after allo-HSCT was 33% in patients with CNS infection and 53% in those without CNS infection (p = .04).
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients are at a high risk for several central nervous system (CNS) complications [1] . These complications arise either from the primary disease for which the patient is undergoing allo-HSCT or as a consequence of immunosuppressive treatments, infection, or hemorrhage that may develop following allo-HSCT [2] [3] [4] . Although CNS infection usually results in a dismal outcome, early diagnosis and immediate treatment intervention may improve prognosis [5, 6] . The incidence of CNS infection ranges from 0.8% to 15% [7] [8] [9] [10] [11] [12] [13] [14] , and various causative pathogens, including bacteria [15] , fungi [9, 14] , viruses [7, [16] [17] [18] [19] [20] , and protozoa [21] , have been identified, but the full spectrum of pathogens is not known. Multiple factors, including severe graftversus-host disease (GVHD) or use of high doses of an immunosuppressive drug, such as alemtuzumab, were identified as risk factors for CNS infection. However, little is known about the precise clinical characteristics of CNS infection, as clinical manifestations may be difficult to distinguish from other conditions that cause neurological symptoms [8, [11] [12] [13] 22, 23] . This study described the clinical course of 17 cases of CNS infection among 353 allogeneic transplant recipients over the previous 6 years at a single institution and reviewed their clinical outcomes.
Materials and methods

Patient demographics
We retrospectively reviewed 353 patients (210 men and 143 women; median age, 43 years; range, 16-73 years) with various diseases who underwent allo-HSCT at our institution. Between January 2005 and December 2011, 261 patients underwent bone marrow transplantation (82 related, 179 unrelated), 48 underwent related peripheralblood stem cell transplantation, and 44 patients underwent unrelated cord-blood stem cell transplantation. Clinical characteristics of patients are summarized in Table 1 .
Transplantation procedure
Preparative treatment was performed according to the primary disease and type of transplant. Generally, patients with lymphoid malignancy were conditioned using a total body irradiation (TBI)-containing regimen (12 Gy) that included cyclophosphamide (CY) at 120 mg/kg with or without cytarabine at 8 g/m 2 . Conversely, patients with myeloid malignancy were conditioned using a non-TBI-containing regimen that included oral busulfan (BU) at 16 mg/kg or intravenous BU at 12.8 mg/kg and CY at 120 mg/kg. Plasma concentrations of BU were not monitored. Patients with severe aplastic anemia were also conditioned using a total lymphoid irradiation-containing regimen.
Reducedintensity conditioning regimens consisted of fludarabinebased regimens with or without low-dose TBI. Cyclosporine or tacrolimus plus short-term methotrexate were used for prophylaxis. Tacrolimus was used in cases of unrelated or mismatched transplantation. Acute and chronic GVHD were diagnosed and graded according to previously established criteria. Tosufloxacin and fluconazole were orally administered 14 days before allo-HSCT for prophylaxis against bacterial and fungal infection, respectively. For patients with a high risk of invasive fungal infections, voriconazole was administered instead of fluconazole. Trimethoprim and sulfamethoxazole were administered to prevent Pneumocystis pneumonia. Acyclovir was administered to prevent herpes simplex virus infection until the end of administration of immunosuppressive drugs. Cytomegalovirus (CMV) disease monitoring using an antigenemia assay for pre-emptive ganciclovir therapy was performed.
Diagnostic procedure for CNS infection and statistical analysis
According to the standard operating procedure at our institution, symptomatic patients with an altered mental status or convulsions, particularly those without any other identified causes of neurological dysfunction, such as hemorrhage [4] , metabolic disorder, or drug toxicity, were classified as possibly having CNS infection. These patients immediately underwent cerebrospinal fluid (CSF) examination with standard culturing, staining for bacterial, viral, and protozoan pathogens, and polymerase chain reaction (PCR) testing for human herpesvirus virus 6 (HHV-6), varicella zoster virus (VZV), herpes simplex virus, CMV, and adenovirus. When progressive multifocal leukoencephalopathy was considered, PCR for John Cunningham (JC) virus in the CSF was employed.
Descriptive statistics were provided for patient-baseline characteristics. Patient-, disease-, and transplant-related variables were compared using Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. The probability of CNS infection was calculated using the cumulative incidence-function method and considering death without CNS infection as a competing event. To evaluate the association between pretransplant clinical factors and CNS infection, a logistic regression model was used. Overall survival (OS) was calculated using the Kaplan-Meier method and compared with the log-rank test. OS was calculated from transplantation to death regardless of cause. Multivariate analyses were performed using the Cox proportional-hazards model. The following covariates were included in the multivariate analysis: age, sex, disease risk, stem cell source, donor type, conditioning regimen, GVHD prophylaxis, and the development of CNS infection. Variables with p < .10 in the univariate analyses were subjected to multivariate analysis. Development of CNS infection was treated as a time-dependent covariate. All p-values were two-sided, and a p < .05 was considered statistically significant.
Results
Clinical features of CNS infection following allo-HSCT
The charts of 353 allo-HSCT recipients were retrospectively reviewed for CNS infection. Table 1 summarizes the charac-teristics of these 353 patients. Of these patients, 17 eventually developed CNS infection at a median of 38 days (range, 10-1028 days) after allo-HSCT. The median age at the time of CNS infection was 43 years (range, 25-64 years), and nine patients were men (53%). Most patients underwent unrelated HSCT with a myeloablative-conditioning regimen (Table 1) . No patients with CNS infections received antithymocyte globulin as a conditioning regimen. The cumulative incidence of CNS infection was 4.1% at 1 year and 5.5% at 5 years after allo-HSCT. High-risk-disease status was a significant clinical factor for CNS infection according to univariate analysis (p = .01), and this factor remained significant according to multivariate analysis (relative risk = 4.56; 95% confidence interval, 1.28-16.2; p = .02). The 5-year cumulative incidence of CNS infection in patients with high-risk-disease status was 8.8%, whereas the incidence was 1.8% in patients with low-risk-disease status ( Fig. 1) .
Of the 17 patients who developed CNS infection (Table 2) , the types of CNS infection were meningitis (n = 5), encephalitis (n = 3), meningoencephalitis (n = 6), brain abscess (n = 2), and progressive multifocal leukoencephalopathy (n = 1). The causative pathogens were HHV-6 (n = 6), enterococcus (n = 2), staphylococcus (n = 2), streptococcus (n = 2), VZV (n = 1), CMV (n = 1), JC virus (n = 1), Note. ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; BM = bone marrow; CB = cord blood; CML = chronic myeloid leukemia; CNS = central nervous system; CyA = cyclosporine; FK = tacrolimus; GVHD = graft-versus-host disease; MDS = myelodysplastic syndrome; ML = malignant lymphoma; PBSC = peripheral blood stem cell; SAA = severe aplastic anemia. a Disease risk was classified into two categories: high risk included acute leukemia not in remission, myelodysplastic syndrome with excess blast count, or chronic myelomonocytic leukemia and the others were classified as low risk. Low risk High risk Figure 1 Cumulative incidence of the development of CNS infection following allo-HSCT. The incidences for patients with high-risk-disease status versus those with low-risk-disease status are shown. Note. Allo-HSCT = allogeneic hematopoietic stem cell transplantation; CNS = central nervous system. Note. ACV = acyclovir; ADV = adenovirus; ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; ATL = adult T cell leukemia; BU = busulfan; CA = cytarabine; CB = cord blood; CML = chronic myeloid leukemia; CMV = cytomegalovirus; CNS = central nervous system; CSF = cerebrospinal fluid; CT = computed tomography; CTRX = ceftriaxone; CY = cyclophosphamide; CyA = cyclosporine; DHPG = ganciclovir; F = female; FK = tacrolimus; GVHD = graft-versus-host disease; HHV-6 = human herpesvirus 6; JCV = John Cunningham virus; LZD = linezolid; M = male; MDS = myelodysplastic syndrome; MEPM = meropenem; MMF = mycophenolate mofetil; MRI = magnetic resonance imaging; NA = not applicable; ND = not done; PML = progressive multifocal leukoencephalopathy; RBM = related bone marrow; RPB = related peripheral blood stem cell; sMTX = short-term methotrexate; ST = trimethoprim/sulfamethoxazole; TBI = total body irradiation; UBM = unrelated bone marrow; VCM = vancomycin; VZV = varicella zoster virus; WBC = white blood cell; S capitis = Staphylococcus capitis; S haemolyticus = Staphylococcus haemolyticus; S pneumonia = Streptococcus pneumoniae.
adenovirus (n = 1), and Toxoplasma gondii (n = 1). All 10 cases of viral infections were diagnosed with a PCR assay of CSF, and the six cases of bacterial infections were diagnosed with bacterial culture of CSF or abscess. Toxoplasmosis was diagnosed following a brain autopsy. At the onset of CNS infection, 10 patients (59%) were receiving steroids for GVHD treatment. Fourteen patients (82%) developed an altered mental status, and one patient developed convulsions. Seven patients (41%) showed fever (>38°C), and high blood pressure (systolic blood pressure > 160 mmHg or diastolic blood pressure > 90 mmHg) was observed in five patients. Engraftment had been achieved in 12 patients (71%) at the onset of CNS infection. Lumbar puncture was performed in 16 patients, and cell counts were elevated in five of these patients (31%). Median cell counts were 3 mm À3 (range, 0-4208 mm À3 ), and protein levels were elevated in nine patients (53%). Cranial computed tomography was performed in nine patients, but the results were essentially normal in all of the patients. Magnetic resonance imaging was performed in 14 patients, and nine patients (64%) displayed abnormal findings (Table 2 ). Abnormalities in the medial temporal lobe were observed in three of the six patients with HHV-6 infection. The median onset time of HHV-6 infection seemed to be earlier as compared with that of other CNS infections, although the difference was not statistically significant (26 days vs. 121 days; p = .18). (see Table 3 ) Table 2 . The probability of an overall response was 53%; however, minor neurological symptoms remained in four patients (data not shown). Foscarnet was administered to all six patients with HHV-6 infection. Of these patients, two improved completely, but the remaining four improved with minor neurological symptoms or did not respond to the treatment. We were able to analyze sequential HHV-6 PCR values in three patients (Cases 1, 2, and 6), and in each patient, HHV-6 copy number in CSF decreased after initiation of foscarnet treatment (Case 1: HHV-6 PCR positive to negative; Case 2: 3000 copies/mL to undetectable; and Case 6: from 77,000 copies/mL to 150 copies/mL). For VZV meningitis (Case 7), CMV encephalitis (Case 8), and progressive multifocal leukoencephalopathy due to JC virus (Case 9), acyclovir, foscarnet, and mefloquine were administered, respectively. The patient with toxoplasmosis (Case 11) developed respiratory failure with diffuse bilateral infiltrates at the onset. Pneumocystis pneumonia was initially suspected, and, therefore, sulfamethoxazole-trimethoprim was administered. At autopsy, the brain of the patient showed widespread necrotizing tissue in the caudate nucleus, basal ganglia, thalamus, hippocampus, cerebrum, cerebellum, midbrain, and pons, with abundant Toxoplasma gondii cysts and free tachyzoites (trophozoites). Toxoplasma cysts were also visualized in the lung, thyroid, stomach, uterus, ovary, and peritoneum. For the six patients with bacterial meningitis, a bulk dose of antibiotics was intravenously administered. Two patients responded completely, and one patient improved with persistent memory impairment.
Treatment and outcome
A summary of treatments for CNS infection is presented in
As shown in Fig. 2 , OS in patients with CNS infection was significantly inferior to that observed in those without CNS infection (33% vs. 53% at 3 years; p = .04). Only six patients were alive at a median follow-up of 39 months (range, 1-58 months) after diagnosis of CNS infection. The median OS after the onset of CNS infection as determined using the Kaplan-Meier method was only 107 days. Only four patients simultaneously developed systemic infection documented by blood culture or autopsy. Causative pathogens for systemic infection were enterococcus (Cases 12 and 13), Streptococcus pneumoniae (Case 16), and Toxoplasma gondii (Case 11). The main cause of death was CNS infection in six patients, other infections in three patients, and disease progression in two patients ( Table 2) .
Discussion
In our series, 4.8% of allo-HSCT recipients developed CNS infection at a median of 38 days after transplantation. The incidence of CNS infection varies from 0.8% to 15% Note. CI = confidence interval; CNS = central nervous system; RR = relative risk. No CNS infection CNS infection Figure 2 OS following allo-HSCT for patients with and without CNS infection. Note. Allo-HSCT = allogeneic hematopoietic stem cell transplantation; CNS = central nervous system; OS = overall survival. [7] [8] [9] [10] [11] [12] [13] [14] , with the discrepancy in these incidences possibly due to differences in study design, patient population of the studies, definition of CNS infection, or prophylactic strategies for infections. In a retrospective study of 2628 patients undergoing allo-HSCT, Schmidt-Hieber et al. [7] reported that the incidence of viral encephalitis was 1.2%, a result comparable with ours. Regarding the risk factors for CNS infection, in a retrospective study of 655 patients who underwent allogeneic or autologous transplantation, Maschke et al. [11] revealed that severe GVHD or the use of high doses of immunosuppressive drugs may induce a risk for developing toxoplasma encephalitis. In our study, a highrisk-disease status was an independent risk factor for CNS infection, which may be attributed to the immunosuppressive status due to multiple courses of intensive chemotherapy before transplantation. The prognosis of patients with CNS infection after allo-HSCT is extremely poor. SchmidtHieber et al. [7] reported that the median survival after the onset of viral encephalitis was only 94 days, with higher mortality in patients with rather than those without viral encephalitis. In our study, the median OS after the onset of CNS infection was 107 days, and OS at 3 years after allo-HSCT was 33%, similar to a report by Maschke et al. [11] Although in four cases it appeared that CNS disease was secondary to a systemic infection, most of the patients developed sole manifestation of the pathogen. Therefore, the worse 3-year OS observed among patients with CNS infections was a direct consequence of CNS infection. Among our 17 cases of CNS infection, viruses accounted for 58%, bacteria for 36%, and protozoa for 6%; however, no fungal CNS infection was observed in our series. Maschke et al. [11] reported that cerebral aspergillosis was the second most common CNS infection post-transplantation. In another autopsy series of 180 transplant recipients, 27 patients had an infection in the brain parenchyma, and fungi were isolated in up to 60% of their cases [10] . The discrepancy in the causative pathogens may be due to differences in prophylactic strategies or the choice of diagnostic modalities for CNS infection.
Regarding HHV-6 meningoencephalitis, although all six patients received foscarnet relatively early in their clinical courses, only two showed good cognitive recovery, and four continued to have memory impairment or disorientation. Moreover, most patients died during follow-up, although no patients died of HHV-6 meningoencephalitis, similar to previous reports showing that >50% of patients with HHV-6 meningoencephalitis died of encephalitis-unrelated causes, such as GVHD and other infections [24, 25] . Although incidental positivity of CSF PCR for HHV-6 in chromosomally integrated HHV-6 (ciHHV-6) patients with CSF pleocytosis may result in erroneous diagnosis of HHV-6 meningoencephalitis [26] , considering that all six patients developed typical clinical features of HHV-6 meningoencephalitis, the possibility of misdiagnosis due to ciHHV-6 seems unlikely.
We also focused on the initial clinical findings of CNS infection; however, not surprisingly, we found no specific features in our series. Although most patients presented with altered mental status as the initial manifestation, <50% of patients developed fever (>38°C), and convulsions were observed in only one patient with HHV-6 infection. In a retrospective study of 1461 allo-HSCT cases, CNS infection was documented in 14 (17.7%) out of 79 patients with convulsions [27] . Thus, the initial manifestation of CNS infection may be very similar to that of other disorders, such as cerebrovascular disease, metabolic disorder, and drug toxicity [5, 10, 23, 25] . Therefore, a positive diagnostic strategy, including PCR testing of CSF for virus infection and magnetic resonance imaging rather than computer tomography, may be needed to reach an accurate diagnosis, although not all positive cultures or PCR-testing results are reflective of the true infection and results should be interpreted with caution.
This study had a limitation due to its retrospective nature. Additionally, we may have overlooked some patients with CNS infection, despite detailed database analysis and extensive chart review. Nevertheless, our aim was to review the clinical outcomes of 353 allogeneic transplant patients after CNS infection over a 6-year period and to provide useful insights into this phenomenon.
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